Enrolling by invitationPhase 3NCT04208529
A Long-term Follow-up Study in Participants Who Received CTX001
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Intervention
- CTX001(biological)
- Enrollment
- 160 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2021 – 2039
Study locations (20)
- Lucile Packard Children's Hospital, Palo Alto, California, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago - Hematology, Chicago, Illinois, United States
- Herbert Irving Pavilion - Hematology, New York, New York, United States
- New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York, New York, United States
- Levine Children's Hospital - Hematology, Charlotte, North Carolina, United States
- The Children's Hospital of Philadelphia - Hematology, Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- TriStar Medical Group Children's Specialists - Pediatric Oncology, Nashville, Tennessee, United States
- Methodist Healthcare System of San Antonio, Methodist Hospital, Methodist Children's Hospital, San Antonio, Texas, United States
- Hopital Universitaire des Enfants Reine Fabiola (HUDERF) - Hematology, Brussels, Belgium
- Hospital for Sick Children - Hematology, Toronto, Canada
- Toronto General Hospital - Hematology, Toronto, Canada
- St. Paul's Hospital - Hematology, Vancouver, Canada
- University Hospital Duesseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology, Düsseldorf, Germany
- Center for Pediatric Clinical Studies (CPCS), Klinik Für Kinder- Und Jugendmedizin, Germany
- +5 more locations on ClinicalTrials.gov
Collaborators
CRISPR Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04208529 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Beam Therapeutics Inc.
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGPHASE3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited